Form D · Biotechnology

Axion BioSystems, Inc.

Atlanta, GA · CIK 0001458565

Offering snapshot reported Oct 5, 2018 · SEC filing

Reported sold
$8M
Offering amount: $8M
Investors reported
31
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Sep 27, 2018
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 5, 2018Initial$8,000,380No comparison31SEC filing
May 17, 2016Initial$6,265,603No comparison16SEC filing
May 9, 2012Initial$3,208,768No comparison17SEC filing
Jul 28, 2010Initial$2,100,079No comparison10SEC filing
Apr 30, 2009Initial$1,000,113No comparisonNot reportedSEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-322955

Source: Form D, filed Oct 5, 2018. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Mark Allen Director
Julian A. Bragg Executive
Edgar Brown Executive
Greg Dane Director
Stephen De Weerth Executive
Glenn Epstein Director
David Gibson Director
Michelle Jarrard Director
Thomas J. O'brien Director, Executive
Swaminathan Rajaraman Executive
James Ross Director, Executive
Jay Teich Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1819 Peachtree Road Ne Suite 350
Atlanta, GA, 30309